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1. Introduction
With  the  advent  of  multifunctional  nano  delivery  systems,  simultaneous  imaging  and
therapy  aspires  to  detect  and  treat  tumors  at  a  very  early  stage  with  promising  out‐
comes.  In  this  context,  numerous  anti-cancer  drug/gene delivery  systems have been ex‐
plored  with  the  primary  aim  to  increase  the  treatment  efficacy  without  compromising
safety.  Secondary  goals  include  enhancing  bioavailability,  specific  targeting,  apart  from
the enhanced stability of the formulation [1]. The multifaceted applications of nanoparti‐
cles are the direct result of their ability to deliver high pay loads of drugs or biomarkers
to the desired sites within the body. Design and development of tumor specific nanopar‐
ticles  could  significantly  amplify  the  delivering  capacity  to  a  specific  target  of  interest,
without  affecting  healthy  cells  [2].  Technological  advances  in  nanomaterials  and  nano‐
technology  have  paved  the  way  for  several  carriers  such  as  liposomes  [3],  dendrimers
[4], and micelles [5], solid lipid nanoparticles (SLN) [6] and recently nanostructured lipid
carriers  [1,  7].  Polymeric  micelles,  or  nanosized (~10–100 nm) supramolecular  constructs
composed of amphiphilic block-copolymers, are emerging as powerful drug delivery ve‐
hicles for hydrophobic drugs. Liposomes are currently the most popular nanosized drug
delivery systems, with one or several lipid bilayers enclosing an aqueous core. Liposome-
encapsulated formulations of doxorubicin earlier approved for the treatment of Kaposi’s
sarcoma, are now used against breast cancer and refractory ovarian cancer. Breast cancer
in particular  has been the focus of  many studies  involving liposome-based chemothera‐
peutics, in part due to the clinical success of various drugs such as Doxil, which is a lip‐
osomal formulation currently used to treat recurrent breast cancer [7].  The anthracycline
doxorubicin  is  the  active  cytotoxic  agent  and  is  contained  within  the  internal  aqueous
core of the liposome. The encapsulation of doxorubicin within liposomes significantly re‐
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duces the cardiotoxicity that commonly results from the use of unencapsulated anthracy‐
clines  by  decreasing the  amount  of  the  drug being delivered to  the  heart  [7].  As  such,
patients can receive much higher doses of the chemotherapeutic in the liposomal formu‐
lation compared to  unencapsulated,  thereby allowing tumor tissue  to  potentially  be  ex‐
posed  to  a  lethal  dose  of  the  drug  while  minimizing  deleterious  side  effects.  This
inherent  advantage  associated with  the  use  of  liposomes as  drug delivery  vehicles  also
serves to minimize the many other toxic side effects associated with doxorubicin includ‐
ing gastrointestinal toxicity and complications arising from myelosuppression.
Each delivery system however,  has its  advantages and limitations.  Advantages afforded
for  drug delivery include the presence of  an inner  core  for  lipophilic  drug entrapment,
as  well  as  a  hydrophilic  outer  shell  that  prevents  particle  aggregation and opsonisation
[8].  This  complexation prevents  uptake by the  reticuloendothelial  system (RES),  thereby
improving circulation times which,  combined with nanoscale  sizing,  confers  preferential
accumulation in tumor tissue. In general, nanovectors can be targeted to tumors by pas‐
sive and active targeting approaches, where a passive strategy takes advantage of a nan‐
vector’s  small  size  permitting  it  to  penetrate  and  accumulate  in  the  tumor.  Most  solid
tumors are sustained by extensive angiogenesis  leading to hypervascular  tissue with an
incomplete vascular architecture. They also have an impaired lymphatic drainage and an
increased production of permeability factors resulting in the accumulation and inefficient
clearance of  nanoparticles  leading to the enhanced permeability and retention effect  [9].
The hyperpermeable nature of  tumor vasculature is  characterized by a pore cut off  size
ranging between 380 and 780 nm allowing particles less than 780 nm to extravasate into
the  tumor interstitium [10].  In  addition,  active  targeting to  various  tissues  may be  ach‐
ieved via  utilization of  ligands on the surface of  nanoparticles,  reducing the side effects
to the normal tissue by limiting drug/gene distribution to the target organ [11]. An excel‐
lent  example  is  Abraxane,  an  albumin  bound  nanoparticle  formulation  of  Paclitaxel
(PTX),  approved by FDA in  January 2005  for  the  treatment  of  metastatic  breast  cancer.
Abraxane has been shown to outperform standard PTX in the treatment of breast cancer
[12].  Utility of this drug was initially limited due to its poor aqueous solubility [13],  re‐
quiring use of an excipient, Cremophor, which is satisfied by novel engineered nanovec‐
tors.  A  recent  Gynecologic  Oncology  Group  Phase  II  evaluation  of  albumin-bound
paclitaxel nanoparticles to treat recurrent or persistent platinum-resistant ovarian, fallopi‐
an tube, or primary peritoneal cancer, concluded that these nanoparticles are as effective
and tolerable in their cohort of refractory ovarian cancer patients previously treated with
paclitaxel  [14].  Nanoparticles  fabricated  with  albumin  [15],  poly(lactic-co-glycolic  acid)
[16]  and poly  lactic  acid  have also  been loaded with  PTX and used to  passively  target
tumors.  Albumin has been shown to be nontoxic,  non-immunogenic,  biocompatible  and
biodegradable making it  an ideal  candidate to fabricate nanoparticles  for  drug delivery.
Site-specific  drug delivery allows for  the  clinical  translation of  chemotherapeutic  agents
with safer targeted cell killing, that are otherwise abandoned due to insolubility, toxicity
and  safety  concerns.  Moreover,  these  new  delivery  devices  can  preferentially  confine
treatments to tumors within the nodal space while sparing healthy tissues.
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2. Solid lipid nanoparticles
Solid lipid nanoparticles [17] or lipospheres are rapidly emerging as new class of safer and
efficient gene/drug delivery vectors. SLNs are sub-micron colloidal carriers, ranging from 50
nm to 1 μm, that are composed of physiological lipid dispersed in water or in aqueous
surfactant solution (Figure 1). SLNs function as an alternative drug carrier system to other
novel delivery approaches such as emulsions, liposomes, and polymeric nanoparticles. SLNs
offer several advantages conferred by their colloidal dimensions including: i) feasibility of
incorporation of lipophilic and hydrophilic drugs; ii) improved physical stability; iii) control‐
led release; iv) improved biocompatibility; v) potential for site specific drug delivery; vi)
improved drug stability; vii) better formulation stability; viii) the ability to freeze dry and
reconstitute; ix) high drug payload; x) controllable particle size; xi) the avoidance of carrier
toxicity; xii) low production cost; and xiii) easy scale-up and manufacturing [18]. In addition,
significant toxicity and acidity associated with a number of biodegradable polymeric materials
are not observed with SLNs. And, in contrast to emulsions and liposomes, the particle matrix
of SLNs is composed of solid lipids. SLNs can be prepared using wide variety of lipids
including lipid acids, mono- (glycerol monostearate), di- (glycerol bahenate) or triglycerides
(tristearin), glyceride mixtures or waxes (e.g. cetyl palmitate) and stabilized by the biocom‐
patible surfactants(s) of choice (non-ionic or ionic). Lipids most commonly used are triglycer‐
ide esters of hydrogenated fatty acids, including hydrogenated cottonseed oil (Lubritab™ or
Sterotex™), hydrogenated palm oil (Dynasan™ P60 or Softisan™ 154), hydrogenated castor
oil (Cutina™ HR), and hydrogenated soybean oil (Sterotex™ HM, or Lipo™) as typical
examples [19]. Various emulsifiers and their combination (Pluronic F 68, F 127) have also been
added to stabilize the lipid dispersion by more efficiently preventing particle agglomeration.
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Figure 1. Schematics of Functionalized Solid Lipid Nanoparticles
The disavantages associated with SLNs relate mostly to their preparation, which generally
involves high pressure and rapid temperature changes that can lead to high pressure-induced
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drug degradation, lipid crystallization, gelation phenomena and the co-existence of several
colloidal species [20]. The drug loading capacity of a conventional SLN is limited by the
solubility of drug in the lipid melt, the structure of the lipid matrix and the polymeric state of
the lipid matrix. If the lipid matrix consists of highly similar molecules (i.e. tristearin or
tripalmitin), a perfect crystal with few imperfections is formed. Since incorporated drugs are
located between fatty acid chains, between the lipid layers and also in crystal imperfections,
a highly ordered crystal lattice cannot accommodate large amounts of drug. This may also lead
to the fast release of a large dose of drug initially, generally known as “burst effect”, followed
by slow and incomplete release of drug. Since high lipid crystallinity is the major cause of burst
release of drug from SLNs, this undesirable phenomenon may be minimized by choosing lipids
that do not form good crystals, including mono- or di-glycerides, or triglycerides with chains
of different lengths. For this reason, in formulation design use of more complex lipids is
recommended for higher drug loading. Nanostructured lipid carriers or NLCs were designed
to overcome these disadvantages with the main goal to increase drug loading and prevent
drug expulsion [21]. For NLCs, the highest drug load could be achieved by mixing solid lipids
with small amounts of liquid lipids (oils). These types of NLCs are called multiple types NLC,
and are analogous to w/o/w emulsions since it is an oil-in-solid lipid-in-water dispersion.
3. SLN preparation methods
There are two main established SLN synthesis techniques, namely, the high-pressure homog‐
enisation technique described by Müller and Lucks [21], and the microemulsion-based
technique described by Gasco [22, 23]. SLNs are prepared from lipid, emulsifier and water/
solvent using different methods, discussed below.
3.1. High Pressure Homogenization (HPH)
High Pressure Homogenization (HPH) is a very reliable technique in the production of SLNs.
High pressure homogenizers are employed to push a liquid with high pressure (100–2000 bar)
and the fluid accelerates on a very short distance to very high velocity (>1000 Km/h).. Very
high shear stress and cavitation forces disrupt the particles down to the submicron range.
Generally 5-10% lipid content is used but up to 40% lipid content has also been investigated.
Typical SLNs production conditions are 500 bar and two or three homogenisation cycles. Two
general approaches of HPH are hot and cold homogenization, both working on the same
concept of mixing the drug in bulk of lipid melt.
3.1.1. Hot homogenization
Hot homogenization is carried out at temperatures above the melting point of the lipid and
can therefore be regarded as the homogenization of an emulsion (Figure 2). A pre-emulsion
of the drug loaded lipid melt and the aqueous emulsifier phase (same temperature) is obtained
by high-shear mixing device. The quality of the pre-emulsion affects the quality of the final
product to a great extent and it is desirable to obtain droplets in the size range of a few
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micrometers. HPH of the pre-emulsion is carried out at temperatures above the melting point
of the lipid. Usually, lower particle sizes are obtained at higher processing temperatures
because of lowered viscosity of the lipid phase [24].
Hot homogenisation is the most frequently applied technique in which even temperature
sensitive compounds can be processed because of the short exposure time to the elevated
temperatures [25]. However, high temperatures increase the degradation rate of the drug and
the carrier. Increasing the homogenization pressure or the number of cycles often results in an
increase of the particle size due to high kinetic energy of the particles. The cold homogenisation
technique is therefore recommended for extremely temperature sensitive compounds and
hydrophilic compounds, which might partition from the liquid lipid phase to the water phase
during the hot homogenisation.
3.1.2. Cold homogenization
During cold homogenization, the drug containing lipid melt is cooled and, after solidifica‐
tion, the lipidic mass is ground to yield lipid microparticles [26]. The lipid microparticles are
dispersed in cold surfactant solution by stirring, yielding a macro-suspension. This suspen‐
sion is then passed through a high-pressure homogeniser at or below room temperature,
where the microparticles are broken down to solid lipid nanoparticles. However, compared
to hot homogenization, larger particle sizes and a broader size distribution are typical of
cold homogenized samples.
3.1.3. Ultrasonication or high speed homogenization
SLNs are also developed by high speed stirring or sonication [27]. The ultrasonic dispersion
may offer an appropriate alternative for laboratory scale productions due to its rapid nature and
the relatively low cost of required apparatus. So far, its suitability has only been evaluated for
SLN [17, 28]. The primary disadvantage of this method is the broader particle size distribution
that is yielded, ranging into the micrometer range. Potential metal contamination due to ultra‐
sonication is another issue presented by this method. To generate more stable formulations,
high speed stirring and ultrasonication may be used in combination at high temperature.
3.2. Solvent emulsification/evaporation
In this method, the lipidic material, such as glyceride is dissolved in an organic solvent (e.g.
chloroform, cyclohexane) and the solution is emulsified in an aqueous phase [29]. After
evaporation of the solvent the lipid precipitates to form nanoparticles with a mean diameter
of around 30 nm using cholesterol acetate as a model drug and lecithin/sodium glycocholate
blend as an emulsifier [30]. The solution is emulsified in an aqueous phase by high pressure
homogenization and the organic solvent is removed from the emulsion by evaporation un‐
der reduced pressure (40–60 mbar).
3.3. Supercritical fluid
This platform technology, with several variations for powder and nanoparticle preparation,
is a relatively new technique for SLN production and offers the advantage of solvent-less
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processing [31]. SLNs can be prepared by the rapid expansion of supercritical carbon dioxide
solutions (RESS) method, where carbon dioxide (99.99%) is a good choice as solvent.
4. Microemulsion method
This method is based on the dilution of microemulsions that are two-phase systems composed
of an inner and outer phase (e.g. o/w microemulsions) [32]. They are made by stirring an optical‐
ly transparent mixture at 65-70°C, which typically composed of a low melting fatty acid (e.g.
stearic acid), an emulsifier (e.g. polysorbate 20), co-emulsifiers (e.g. butanol) and water. The hot
microemulsion is dispersed in cold water (2-3°C) with stirring. SLN dispersion can be used as
granulation fluid for transferring into solid product (tablets, pellets) by granulation process, but
in case of low particle content, excess water must first be removed. High-temperature gradients
facilitate rapid lipid crystallization and prevent aggregation. Due to the dilution step, achieva‐
ble lipid contents are considerably lower compared with the HPH based formulations.
Figure 2. Partitioning effects on drug during the hot homogenization technique production of SLNs. Left: Partitioning
of drug from the lipid phase to the water phase at increased temperature. Right: Re-partitioning of the drug to the
lipid phase during cooling of the produced O/W nanoemulsion. Source: Muller RH et al. Solid lipid nanoparticles (SLN)
for controlled drug delivery - a review of the state of the art. European Journal of Pharmaceutics and Biopharmaceu‐
tics 50: (2000) 161-177.
Novel Gene Therapy Approaches58
4.1. Spray drying method
Spray drying is an alternative procedure to lyophilization in the transformation of an aqueous
SLN dispersion into a solid drug product. This method results in particle aggregation due to
high temperature, shear forces and partial melting of the particle. The use of lipid with melting
point >70°C for spray drying is recommended [33]. Best results are obtained with an SLN
concentration of 1% in a solution of trehalose in water or 20% trehalose in ethanol-water
mixtures (10/90 v/v).
4.2. Double emulsion method
For the preparation of hydrophilic loaded SLN, double emulsion method, a novel approach
based on solvent emulsification-evaporation can be employed. Here, the drug is encapsulated
with a stabilizer to prevent drug partitioning to external water phase during solvent evapo‐
ration in the external water phase of w/o/w double emulsion [34]
5. SLNs cellular uptake, pharmacokinetics and bio-distribution
Research on cellular uptake mechanisms has repeatedly demonstrated that endocytosis is
the preferred route of  internalization of  non-viral  gene vectors  via a  number of  distinct
endocytic  processes.  The  most  studied  mechanisms  include  macropinocytosis,  circular
dorsal  ruffles,  clathrin-mediated  endocytosis  and  several  clathrin-independent  endocytic
pathways [35].  Endocytic uptake mechanisms are highly dependent on cell  type and on
the nature of  gene vectors  [36].  Clathrin-mediated processes  are  limited to particles  un‐
der  200  nm  in  size,  whereas  caveolae-dependent  uptake  prevails  for  particles  between
200 and 500 nm [37]. The prevalent pathway for the cell internalization of PEI polyplex‐
es is however, clathrin-dependent [38].
Apart  from overcoming cellular  barriers  of  uptake,  an anticancer  drug must  be  specifi‐
cally  targeted  to  the  tumor  in  order  to  maximize  its  therapeutic  effect,  and  therefore
biodistribution  studies  are  critical  to  assess  the  safety  of  a  nanomedicine.  However,
since  most  groups  work  on  healthy  instead  of  tumor-bearing  animals,  it  is  difficult  to
confirm whether  SLNs can  lead to  increased tumor  drug concentrations  by  way of  en‐
hanced  permeability  and  retention  [9].  Recently,  Zhang  et  al.  (2010)  evaluated  antitu‐
mor  efficacy  of  docetaxel-loaded  solid  lipid  nanoparticles  (DSN)  in  a  murine  ovarian
cancer  model  [39].  In  this  study,  SLN biodistribution from RES more toward the circu‐
lation  system  was  observed.  Moreover,  SLNs  in  comparison  to  the  free  drug  demon‐
strated  more  potent  in  vivo  anti-ovarian  cancer  activity  with  improved
pharmacokinetics.  In  contrast,  paclitaxel  loaded  in  pegylated  solid  lipid  nanoparticles
were  mainly  taken  up  by  the  RES  after  intravenous  administration  in  rats,  showing  8-
fold  and  3-fold  higher  levels  in  liver  and  spleen,  respectively,  8  h  after  administration
compared to  paclitaxel  in  Taxol® [40].  Moreover,  paclitaxel  levels  in  kidney,  heart  and
lung  were  indistinguishable  between  the  two  formulations.  The  difference  in  biodistri‐
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bution  of  SLNs  reported  in  literature  may  be  due  to  several  factors  including  varia‐
tions in size,  surface functionalization and composition.
The  biodistribution  of  an  anticancer  drug  delivered  by  SLN  may  be  further  man‐
oeuvred  by  route  of  injection  to  achieve  the  desired  therapeutic  goal.  Harivardhan
Reddy  et  al.  (2005)  compared  the  biodistribution  of  free  99  mTechnetium-labeled  etopo‐
side  and  radio-labeled  etoposide  loaded  SLNs  in  Dalton's  lymphoma  tumor-bearing
mice  [41].  They  showed  that  administration  via  the  subcutaneous  route  resulted  in
high  tumor  uptake  of  etoposide  and  etoposide  loaded  tripalmitin  nanoparticles  and
was  the  preferred  route  as  compared  to  intravenous  or  intraperitoneal  administration.
However,  elevated  tumor  drug  concentrations  were  also  found  with  intravenously  ad‐
ministered  etoposide  loaded  SLN  in  comparison  to  the  free  drug,  (approximately  67%
increase  1  h  post-injection,  30%  increase  24  h  post-injection).  In  yet  another  study  by
Zara et  al.  (2002)  duodenal  administration of  idarubicin-loaded SLN led to  higher  bioa‐
vailability  than  intravenously  administered  SLNs  [42].  Also,  idarubicin  and  its  main
metabolite,  idarubicinol,  were  detected in  the  brain  after  IDA-SLN administration,  indi‐
cating  that  the  SLNs  were  able  to  pass  the  blood-brain  barrier;  an  attractive  attribute
in the tratement  of  brain tumors.  Thus,  the route of  administration of  SLN formulation
is  a  key  consideration  in  the  design  of  animal  or  clinical  anti-cancer  drug  delivery
studies.
6. SLNs as anti-cancer gene/drug delivery vectors: Challenges and
successes
Solid lipid nanoparticles  have rapidly established themselves during the past  decade as
stable,  reliable  and easy  to  produce  vectors.  SLN advantages  over  other  existing  trans‐
fection  vectors  include  safety,  good storage  stability,  possibility  of  lyophilization  and  a
high degree  of  flexibility  in  design and optimization [25].  Cationic  SLNs can efficiently
bind  DNA  directly  via  ionic  interaction  and  mediate  gene  transfection.  However,  as
with  all  non-viral  vectors,  many cellular  obstacles  have  to  be  overcome to  achieve  sat‐
isfactory  levels  of  transfection  activity:  i)  binding  to  the  cell  surface;  ii)  cellular  inter‐
nalization;  iii)  escape  from  the  endolysosomal  compartment;  and  iv)  translocation
through  the  nuclear  envelope.  In  order  to  surmount  these  barriers,  cationic  SLNs  are
designed  as  multifunctional  “smart”  carriers  for  efficient  gene  expression  [43].  Compo‐
nents  such  as  chitosan  [44]  and  surface  functionalization  moieties  e.g.  poly(styrene-4
sodium  sulfonate)  (PSS)  and  poly(L-lysine  hydrochloride)  (PLL)  [45],  folate–chitosan
and  cholesterol  derivative  (CHETA)  [46],  cetyltrimethyl  ammonium  bromide  (CTAB)
[47]  and a  phyto-ceramide  [48]  and TAT peptides  [49],  may each  individually  assist  in
overcoming the barriers  of  efficient  transfection.  In  addition,  protamine a  cationic  small
protein  rich  in  arginine  exerts  both  DNA  condensation  activity  and  proton  sponge  ef‐
fect  facilitating  endosomal  escape  as  well  as  assisting  nanovectors  to  enter  the  nucleus
owing  to  its  nuclear  localization  signal  (NLS)  [50].  Table  1  lists  some of  the  successful
SLN formulations evaluated as  anti-cancer  agents  in various cancers.
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SLN Composition Characterization Indication Drug/Gene Reference
Stearic acid, DOTAP, Pluronic F68
and
dioleoylphosphatidylethanolami
ne (DOPE)
Size, Zeta Potential Prostate Cancer Plasmid DNA [s51]
Tricaprin as a core, 3beta[N-
carbamoyl] cholesterol (DC-
Chol), DOPE and Tween 80
Size, Zeta Potential,
Differential Scanning
Calorimetry
Lung Cancer Plasmid DNA [52]
Stearic acid, Lecithin and PS Transmission electron
microscopy Lung Cancer Phospho-Sulindac [53]
Poloxamer 188 and Tween 80 Size, Zeta potential Breast Cancer Emodin [54]
Precirol, Compritol, soybean
Phosphatidylcholine, Tween 80 Size, Zeta Potential Breast Cancer Tryptanthrin [55]
Myristic acid, Stearic acid,
Palmitic acid, lauric acid,
poly(ethylene glycol)-100-
stearate (PEG100SA),
poly(ethylene glycol)-40-stearate
(PEG40SA), Hydrolyzed polymer
of epoxidized soybean oil,
Pluronic F68 (PF68) (non-ionic
block copolymer)
Size, Zeta Potential,
Transmission Electron
Microscopy
Breast Cancer Doxorubicin andMitomycin -C [56]
Stearyl alcohol and
cetyltrimethylammonium
bromide (CTAB), Ceramide VI,
polysorbate 60
Size, Zeta Potential Ovarian Cancer
Doxorubicin and mixed-
backbone GCS antisense
oligonucleotides
(MBO-asGCS)
[57]
1,2-Dioleoyl-sn-glycero-3-
ethylphosphocholine 1,2-
diphytanoyl-sn-glycero-3-
phosphatidylethanolamine
(DPhPE), 3â[N-(N′,N′-
dimethylaminoethane)-
carbamoyl] cholesterol (DC-
Chol), 1,2-Dioleoyl-sn-glycero-3-
ethylphosphocholine (EDOPC),
and methoxypolyethylene glycol
2000-distearoyl
phosphatidylethanolamine
(mPEG-DSPE), glyceryl trioleate.
Zeta potential and Gel
retardation Epithelial Cancer Paclitaxel and siRNA [58]
Cholesteryl oleate, glyceryl
trioleate, DOPE, Chol , and DC-
Chol
Size, Zeta Potential Brain Cancer(glioblastomas) c-Met siRNA [59]
Stearic acid, Glyceryl behenate Size, Zeta Potential Skin Cancer Doxorubicin [60]
Table 1. Solid Lipid Nanoparticles loaded with DNA/ Drug as anti-cancer delivery systems in various cancers.
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Nanovectors offer the potential to both detect and treat cancer at a very early stage, thereby
maximizing survival rates. The NCI (National Cancer Institute) Alliance for Nanotechnology
in Cancer provides up-to-date information in nano-cancer research and its promise for cancer
diagnosis and treatment (http://nano.cancer.gov/). Using siRNA molecules loaded in nano‐
vectors, early proof-of-principle experiments in various tumor cells suggest that RNA silencing
may have great potential as a strategy for treating cancer. However, siRNA therapeutics are
hindered by poor intracellular uptake, limited blood stability and undesirable non-specific
immune stimulation [61]. An interesting strategy used to target the vector employs three-
amino-acid peptide, arginine-glycine-aspartic acid (known by its amino acid code RGD) that
binds to integrins, which in turn are involved in angiogenesis, tumor cell growth, metastasis,
and inflammation. Intravenous administration into tumor-bearing mice of nanoparticles
combined with a dual strategy of siRNA inhibiting vascular endothelial growth factor
receptor-2 and RGD peptide ligand attached at the distal end of the polyethylene glycol [40],
conferred selective tumor uptake, and inhibition of both tumor angiogenesis and growth rate,
achieving both tissue and gene selectivity [62]. In February 2012, Calando Pharmaceuticals, in
Pasadena, Canada, and the National Cancer Institute (NCI) entered into a collaborative
development program for a nanoparticle-based siRNA therapeutic aimed at treating neuro‐
blastoma, the most common extracranial solid tumor in children less than five years of age.
Previous attempts to develop targeted nanoparticles were unsuccessful due to the inherent
difficulties of designing and scaling up a particle capable of targeting, long-circulating via
immune-response evasion and controlled drug release. Very recently, Hrkach et al. (2012)
reported the preclinical development and clinical translation of a docetaxel nanoparticle with
prostate-specific membrane antigen, a clinically validated tumor antigen expressed on prostate
cancer cells and on the neovasculature of most non-prostate solid tumors including breast,
head, lung, neck, prostate and stomach [63]. This targeted nanoparticle-based compound
called “BIND-014” is currently the first one to enter clinical trial, although with small number
of only 17 patients. Patients with advanced or metastatic cancer receive an injection of the nano-
drug once every three weeks and are showing signals of efficacy even at relatively low doses.
This initial but positive result shows promise and the potential impact of nanomedicines as a
paradigm shift in the treatment of cancer.
Very recently, Vighi E et al. (2012) developed a multicomponent cationic SLN as a pDNA
delivery vehicle. The formulations were prepared using stearic acid as the main component
in the lipid phase, stearylamine, the main component in the aqueous phase, as cationic agent
and protamine as transfection promoter along with the phosphatidylcholine (SLN–PC),
cholesterol (SLN–Chol) or both (SLN–PC–Chol). Transfection results on various cell lines in
this study revealed the best transfection for SLN–PC–Chol on COS-1 cells (African green
monkey kidney cell line) [64]. However, lower transfection levels than poly [62] were observed
on HepG2 cells (human hepatocellular liver carcinoma cell line), regardless of the SLN
composition. Using COS-1 monkey kidney fibroblast-like cells, SLNs and liposomes formu‐
lated from the same cationic lipids, demonstrated equipotent in vitro transfection efficiencies
[65]. This study suggests that only the lipid composition in the tested lipid-based formulations
affected transfection efficiencies. The intrinsic toxicity that is common in cationic gene delivery
vehicles may also be minimized, while maintaining high transfection efficiency, by selecting
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good combinations of two-tailed cationic lipids and matrix lipids. Hence, structural or
compositional design changes of nanovectors may influence the outcome in relation with cell
physiology, cell internalization pathways and transfection efficiency. The above results
support the use of SLNs to serve as nano/microcarriers for anti-cancer gene therapies.
Under optimised conditions SLNs can be designed to incorporate lipophilic or hydrophilic
drugs and seem to fulfil the requirements for an optimum particulate carrier system. Stability
studies were performed on SLNs loaded with all-trans retinoic acid (ATRA), another com‐
pound that is sensitive to light, heat and oxidants, and quickly degrades into less active
products such as isotretinoin and all-trans-4-oxo [66]. After 3 months of storage at 4 °C, more
than 90% of the ATRA drug molecules in SLN remained chemically intact. This can be
compared to approximately 50% drug degradation when stored at the same temperature in
the form of methanol solution or 1% polysorbate-80 solution for only 1 month. Hence, SLNs
are useful for the protection of anticancer compounds that are sensitive to light, and probably
heat and oxidants as well. In a study conducted by our group, modulatory effects of encap‐
sulated and free forms of sesamol (anti-oxidant and anti-cancer compound) were evaluated
by the topical delivery systems in a skin cancer mice model. Both free sesamol and SLN
dispersion were applied as gels (using 1% w/v of Carbopol 934P®) on the skin of mice.
Encapsulated or nanosesamol was found to safely exert chemopreventive effects by decreasing
the lipid peroxidation levels and increasing the anti-oxidant levels, thereby decreasing the
development and promotion of skin tumors. Immunofluorescence studies of pro- and anti-
apoptotic markers, bcl-2 and bax protein expression revealed higher expression of anti-
apoptotic protein, bcl-2, in the tissue sections of tumor bearing mice in comparison to their
control counterparts and groups which received sesamol treatment, reinforcing the role of bcl-2
in skin carcinogenesis. Higher expression of bax was also observed in sesamol treated animals
as compared to the tumor bearing mice. Up-regulation of bax in the control and sesamol treated
groups suggests that it follows the intrinsic pathway of apoptosis (unpublished results).
Ongoing work by our group compared neutraceutical curcumin-loaded SLNs to the free form
as a chemopreventive topical delivery system in 7,12-dimethylbenz [a]anthracene (DMBA)
induced skin cancer model mice. In order to understand the molecular events underlying
nanocurcumin-mediated chemoprevention, protein expression of various biomolecules e.g.
anti and pro inflammatory cytokines (Il-4 and Il-1β) were analyzed by Western immunoblot‐
ting and immunoflourscence. For cancer induction, male Balb/c mice were subcutaneously
injected with 30 mg/Kg body weight of DMBA (in olive oil) once a week for three weeks. DMBA
skin cancer induced mice were topically applied free and encapsulated curcumin (50mg/Kg
b.w) as a chemopreventive agent from one week before DMBA injection to the experiment’s
end (18 weeks). We found that free and nanocurcumin treatment of DMBA treated mice
reduced the levels of malondialdehyde, a by-product of lipid degradation (Figure 3). Antiox‐
idant analysis revealed increased levels of enzymes (SOD, Catalase, Reduced Glutathione,
Total Glutathione) in encapsulated nanocurcumin treated group as compared to free curcumin
group (Figure 4-7). Immunofluorscence studies and western blot analysis of Il-4 and Il-1β
suggest enhanced anti-inflammatory potential of encapsulated curcumin in comparison to
mice treated with free curcumin. Mice bearing skin tumors showed increased expression of
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pro-inflammatory interleukins when compared to the control, which was decreased on
treatment with curcumin (Figure 8). Furthermore, the immunoflourscence assay of anti-
inflammatory interleukin (IL-4) showed a far greater increase in IL-4 expression by topical
treatment with encapsulated curcumin as compared to the free curcumin in mice bearing skin
tumors (Figure 9).
7. Conclusion
Solid Lipid Nanoparticles serve as efficient and safe DNA/ drug loaded nanosystems in both
the imaging and treatment of cancer. Traditional drug delivery systems are often hindered by
their low bioavailabilty, low solubility, toxicity and rapid clearance. In future, clinicians and
researchers will be able to “tune and time” the amount of DNA/Drug delivery by controlling
the release at specific location thereby minimizing their toxicity and side- effects.
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Figure 3. Effect of encapsulated and free curcumin on lipid peroxidation (LPO) in control and experimental groups.
Control (C), DMBA (D), Free Curcumin (FCC), Free Curcumin + DMBA (FCD), Encapsulated Curcumin (CGC), Encapsulat‐
ed Curcumin + DMBA (CGD).
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Figure 4. Effect of encapsulated and free curcumin on reduced glutathione in control and experimental groups. Con‐
trol (C), DMBA (D), Free Curcumin (FCC), Free Curcumin + DMBA (FCD), Encapsulated Curcumin (CGC), Encapsulated
Curcumin + DMBA (CGD).
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Figure 5. Effect of encapsulated and free curcumin on total glutathione in control and experimental groups. Control
(C ), DMBA (D), Free Curcumin (FCC), Free Curcumin + DMBA (FCD), Encapsulated Curcumin (CGC), Encapsulated Cur‐
cumin + DMBA (CGD).
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Figure 6. Effect of encapsulated and free curcumin on superoxide dismutase in control and experimental groups. Con‐
trol (C ), DMBA (D), Free Curcumin (FCC), Free Curcumin + DMBA (FCD), Encapsulated Curcumin (CGC), Encapsulated
Curcumin + DMBA (CGD).
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Figure 7. Effect of encapsulated and free curcumin on Catalase in control and experimental groups. Control (C ),
DMBA (D), Free Curcumin (FCC), Free Curcumin DMBA (FCD), Encapsulated Curcumin (CGC), Encapsulated Curcumin +
DMBA (CGD).
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Figure 8. Photomicrographs (20X) showing expression of IL-1Beta in paraffin sections by immunofluoroscence after
18 weeks of treatment.
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Figure 9. Photomicrographs (20X) showing expression of IL-4 in paraffin sections by immunofluoroscence after 18
weeks of treatment.
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